Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 36, 2014, Pages 13133-13138

  Ellebedy, Ali H ^a   Krammer, Florian ^b   Li, Gui Mei ^a   Miller, Matthew S ^b   Chiu, Christopher ^a,e   Wrammert, Jens ^a   Chang, Cathy Y ^a   Davis, Carl W ^a   McCausland, Megan ^a,f   Elbein, Rivka ^c   Edupuganti, Srilatha ^a   Spearman, Paul ^a   Andrews, Sarah F ^d   Wilson, Patrick C ^d   Garciá Sastre, Adolfo ^b   Mulligan, Mark J ^a   Mehta, Aneesh K ^a,c   Palese, Peter ^b   Ahmed, Rafi ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f IQVIA   (United States)

Author keywords

Breadth; Immunoglobulin; Neutralization; Stalk

Indexed keywords

IMMUNOGLOBULIN G; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ;

ADULT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; BLOOD; CHEMISTRY; CLINICAL TRIAL; CROSS REACTION; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; PLASMA CELL; VACCINATION; VIROLOGY;

ADULT; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; CROSS REACTIONS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; PLASMA CELLS; VACCINATION;

EID: 84906996647     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1414070111     Document Type: Article

References (40)

1. Rappuoli R, Dormitzer PR (2012) Influenza: Options to improve pandemic preparation. Science 336(6088):1531-1533.
2. Webby RJ, Webster RG (2003) Are we ready for pandemic influenza? Science 302(5650):1519-1522.
3. WHO (2008) Immunization, vaccines and biologicals: Influenza. Available at www.who.int/immunization/topics/influenza/en/. Accessed June 20, 2014.
4. Yu X, et al. (2008) Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 455(7212):532-536.
5. Francis T, Jr (1953) Vaccination against influenza. Bull World Health Organ 8(5-6):725-741.
6. Slifka MK, Antia R, Whitmire JK, Ahmed R (1998) Humoral immunity due to long-lived plasma cells. Immunity 8(3):363-372.
7. Ellebedy AH, Webby RJ (2009) Influenza vaccines. Vaccine 27(Suppl 4):D65-D68.
8. Monto AS (2010) Seasonal influenza and vaccination coverage. Vaccine 28(Suppl 4):D33-D44.
9. Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu Rev Biochem 69:531-569.
10. Ellebedy AH, Ahmed R (2012) Re-engaging cross-reactive memory B cells: The influenza puzzle. Front Immunol 3:53.
11. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W (1982) The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31(2 Pt 1):417- 427.
12. Gerhard W, Yewdell J, Frankel ME, Webster R (1981) Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290(5808):713-717.
13. Corti D, et al. (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120(5):1663-1673.
14. Corti D, et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333(6044):850-856.
15. Dreyfus C, et al. (2012) Highly conserved protective epitopes on influenza B viruses. Science 337(6100):1343-1348.
16. Ekiert DC, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324(5924):246-251.
17. Sui J, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16(3):265-273.
18. Wrammert J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208(1):181-193.
19. Tan GS, et al. (2012) A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol 86(11):6179-6188.
20. Brandenburg B, et al. (2013) Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS ONE 8(12):e80034.
21. Li GM, et al. (2012) Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 109(23):9047-9052.
22. Harris AK, et al. (2013) Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci USA 110(12):4592-4597.
23. Lu Y, Welsh JP, Swartz JR (2014) Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci USA 111(1):125-130.
24. Nabel GJ, Fauci AS (2010) Induction of unnatural immunity: Prospects for a broadly protective universal influenza vaccine. Nat Med 16(12):1389-1391.
25. Pica N, et al. (2012) Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci USA 109(7):2573-2578.
26. Hancock K, et al. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 361(20):1945- 1952.
27. Crotty S, Aubert RD, Glidewell J, Ahmed R (2004) Tracking human antigen-specific memory B cells: A sensitive and generalized ELISPOT system. J Immunol Methods 286(1-2):111-122.
28. Belshe RB, et al.; National Institute of Allergy and Infectious Diseases-Funded Vaccine and Treatment Evaluation Units (2011) Safety and immunogenicity of influenza A H5 subunit vaccines: Effect of vaccine schedule and antigenic variant. J Infect Dis 203(5):666-673.
29. Kashyap AK, et al. (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 105(16):5986-5991.
30. Ledgerwood JE, et al.; VRC 306 Study Team (2011) DNA priming and influenza vaccine immunogenicity: Two phase 1 open label randomised clinical trials. Lancet Infect Dis 11(12):916-924.
31. Whittle JR, et al. (2014) Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol 88(8):4047-4057.
32. Khurana S, et al. (2010) Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2(15):ra5.
33. Krammer F, Palese P (2014) Universal influenza virus vaccines: Need for clinical trials. Nat Immunol 15(1):3-5.
34. Krammer F, Pica N, Hai R, Margine I, Palese P (2013) Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87(12):6542-6550.
35. Sui J, et al. (2011) Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis 52(8):1003-1009.
36. Khurana S, et al. (2013) Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Trans Med 5(200):200ra114.
37. Yewdell JW (2011) Viva la revolucion: Rethinking influenza a virus antigenic drift. Curr Opinion Virol 1(3):177-183.
38. Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705-742.
39. Crotty S, et al. (2003) Cutting edge: Long-term B cell memory in humans after smallpox vaccination. J Immunol 171(10):4969-4973.
40. Wrammert J, et al. (2008) Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453(7195):667-671.